Argos Therapeutics, Inc. (NASDAQ:ARGS) released its quarterly earnings results on Wednesday. The biopharmaceutical company reported ($0.21) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.22) by $0.01, Bloomberg Earnings reports. The firm had revenue of $0.07 million during the quarter, compared to the consensus estimate of $0.10 million. Argos Therapeutics had a negative net margin of 7,103.65% and a negative return on equity of 1,532.49%.

Argos Therapeutics (NASDAQ:ARGS) traded down 8.91085% during midday trading on Thursday, hitting $0.23501. 2,228,041 shares of the stock traded hands. Argos Therapeutics has a 52 week low of $0.23 and a 52 week high of $5.68. The stock’s 50-day moving average price is $0.32 and its 200 day moving average price is $1.17. The company’s market capitalization is $9.72 million.

Several equities analysts have recently issued reports on the stock. Zacks Investment Research downgraded shares of Argos Therapeutics from a “buy” rating to a “sell” rating in a research note on Monday, May 15th. FBR & Co dropped their price target on shares of Argos Therapeutics from $2.00 to $1.20 and set a “mkt perform” rating for the company in a research note on Wednesday, April 19th. Four equities research analysts have rated the stock with a hold rating, The stock has a consensus rating of “Hold” and a consensus price target of $3.23.

COPYRIGHT VIOLATION WARNING: This piece was first posted by Daily Political and is the sole property of of Daily Political. If you are reading this piece on another website, it was stolen and reposted in violation of United States & international trademark and copyright law. The legal version of this piece can be accessed at

About Argos Therapeutics

Argos Therapeutics, Inc (Argos) is an immuno-oncology company. The Company is focused on the development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases based on its technology platform called Arcelis. The Company’s Arcelis technology platform utilizes biological components from a patient’s own cancer cells or virus to generate individualized immunotherapies.

Earnings History for Argos Therapeutics (NASDAQ:ARGS)

Receive News & Ratings for Argos Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Argos Therapeutics Inc. and related companies with's FREE daily email newsletter.